Latest Nektar Therapeutics News & Updates

See the latest news and media coverage for Nektar. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Nektar Therapeutics (Nektar)

Biopharmaceutical company developing autoimmune therapies

nektar.com
Headquarters
San Francisco, United States
Founded year
1990
Company type
Public company
Number of employees
50–700

Last updated

Latest news about Nektar Therapeutics (Nektar)

In short: Nektar Therapeutics raised over $800 million through public offerings and reported positive clinical data for rezpegaldesleukin while facing lawsuits.

Company announcements

  • Nektar

    Nektar Therapeutics reports Q1 2026 financial results

    Cash reaches $731.6M. Revenue $10.9M, net loss $44.9M. Advances rezpegaldesleukin Phase 3 trials. Raises $373.8M in offering.

  • Nektar

    Nektar Therapeutics closes $373.8 million public offering

    The offering includes full exercise of underwriters' option for additional shares sold at $92.00 per share. Gross proceeds are approximately $373.8 million before expenses.

  • Nektar

    Nektar Therapeutics prices upsized $325 million public offering

    Sells 3,532,609 shares at $92 each. Proceeds fund R&D, clinical trials, manufacturing. Closes April 23, 2026.

  • Nektar

    Nektar Therapeutics announces proposed $250M public offering

    The offering includes common stock and pre-funded warrants, with an option for underwriters to buy additional shares. Proceeds will fund R&D, clinical trials, and manufacturing.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Nektar

Track Nektar and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nektar competitors & trending companies

Browse news for competitors to Nektar and other trending companies.